Anti-factor Xa as the preferred assay to monitor heparin for the treatment of pulmonary embolism

CONCLUSION: We observed a low incidence of recurrent thromboembolism or PE-associated mortality utilizing an antiXa titrated UFH protocol. The use of an antiXa based heparin assay to guide heparin dosing and monitoring allows for timely and sustained therapeutic anticoagulation for treatment of PE.PMID:37989523 | DOI:10.1111/ijlh.14207
Source: International Journal of Laboratory Hematology - Category: Hematology Authors: Source Type: research